ZA200509866B - Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer - Google Patents
Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer Download PDFInfo
- Publication number
- ZA200509866B ZA200509866B ZA200509866A ZA200509866A ZA200509866B ZA 200509866 B ZA200509866 B ZA 200509866B ZA 200509866 A ZA200509866 A ZA 200509866A ZA 200509866 A ZA200509866 A ZA 200509866A ZA 200509866 B ZA200509866 B ZA 200509866B
- Authority
- ZA
- South Africa
- Prior art keywords
- activated carbon
- particles
- agent
- transfusion
- preparation
- Prior art date
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims description 255
- 206010028980 Neoplasm Diseases 0.000 title claims description 35
- 201000011510 cancer Diseases 0.000 title claims description 32
- 239000003814 drug Substances 0.000 title claims description 22
- 229940079593 drug Drugs 0.000 title claims description 21
- 238000002360 preparation method Methods 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000003978 infusion fluid Substances 0.000 title description 2
- 239000002245 particle Substances 0.000 claims description 48
- 239000003795 chemical substances by application Substances 0.000 claims description 44
- 238000002347 injection Methods 0.000 claims description 30
- 239000007924 injection Substances 0.000 claims description 30
- 238000001179 sorption measurement Methods 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 229940041181 antineoplastic drug Drugs 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- -1 y-IFN Proteins 0.000 claims description 14
- 238000001990 intravenous administration Methods 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 238000012377 drug delivery Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 6
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 6
- 238000006555 catalytic reaction Methods 0.000 claims description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- 229960002949 fluorouracil Drugs 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- 230000002155 anti-virotic effect Effects 0.000 claims description 4
- 230000010100 anticoagulation Effects 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000007800 oxidant agent Substances 0.000 claims description 4
- 230000001590 oxidative effect Effects 0.000 claims description 4
- 238000011287 therapeutic dose Methods 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 229960000643 adenine Drugs 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- 238000013459 approach Methods 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000001186 cumulative effect Effects 0.000 claims description 3
- 229940104302 cytosine Drugs 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 239000002574 poison Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 229940113082 thymine Drugs 0.000 claims description 3
- 229910052723 transition metal Inorganic materials 0.000 claims description 3
- 150000003624 transition metals Chemical class 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims description 2
- MRBCEWCMDNCIDB-UHFFFAOYSA-N 7h-purin-6-amine;1h-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.NC1=NC=NC2=C1NC=N2 MRBCEWCMDNCIDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004157 Hydrolases Human genes 0.000 claims description 2
- 108090000604 Hydrolases Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000004195 Isomerases Human genes 0.000 claims description 2
- 108090000769 Isomerases Proteins 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 102000003929 Transaminases Human genes 0.000 claims description 2
- 108090000340 Transaminases Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 229910052785 arsenic Inorganic materials 0.000 claims description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 claims description 2
- 239000011362 coarse particle Substances 0.000 claims description 2
- 238000007598 dipping method Methods 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 2
- 150000002291 germanium compounds Chemical class 0.000 claims description 2
- 229910001385 heavy metal Inorganic materials 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 238000005057 refrigeration Methods 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- 239000000126 substance Substances 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000013049 sediment Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 230000018044 dehydration Effects 0.000 description 7
- 238000006297 dehydration reaction Methods 0.000 description 7
- 238000000703 high-speed centrifugation Methods 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 4
- 230000005907 cancer growth Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000008359 toxicosis Effects 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- IVGKSFVQFBMHGU-UHFFFAOYSA-N N[C]O Chemical compound N[C]O IVGKSFVQFBMHGU-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004712 cancer cell adhesion Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 108010015046 cell aggregation factors Proteins 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000008203 tachypnea Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 206010056377 Bone tuberculosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010010969 Cor pulmonale acute Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000009360 Osteoarticular Tuberculosis Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001249696 Senna alexandrina Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006093 Sitall Substances 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 208000022913 acute pulmonary heart disease Diseases 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000011300 routine therapy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031250904A CN1263466C (zh) | 2003-05-06 | 2003-05-06 | 活性炭输液剂、其制备方法及其在制备治疗癌症药中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200509866B true ZA200509866B (en) | 2006-12-27 |
Family
ID=33426298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200509866A ZA200509866B (en) | 2003-05-06 | 2005-12-05 | Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050123613A1 (zh) |
| EP (1) | EP1652528A1 (zh) |
| JP (1) | JP2006525238A (zh) |
| KR (1) | KR20060003072A (zh) |
| CN (1) | CN1263466C (zh) |
| AU (1) | AU2004236381A1 (zh) |
| CA (1) | CA2524924A1 (zh) |
| RU (1) | RU2005137851A (zh) |
| WO (1) | WO2004098620A1 (zh) |
| ZA (1) | ZA200509866B (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2362570C2 (ru) * | 2004-06-02 | 2009-07-27 | Куреха Корпорейшн | Средство для устранения фактора циркуляторной дисфункции |
| KR100853535B1 (ko) * | 2007-03-30 | 2008-08-21 | 주식회사 돌나라한농제약 | 대한약전 규격을 만족하는 약용탄의 제조방법 |
| JP2012167030A (ja) * | 2011-02-10 | 2012-09-06 | Sony Corp | コレステロール低下薬、中性脂肪低下薬、血糖値低下薬、コレステロール吸着剤、吸着剤、中性脂肪吸着剤、健康食品、健康補助食品、栄養機能食品、特定保健用食品、医薬部外品、及び、医薬品 |
| HUE036432T2 (hu) * | 2011-10-07 | 2018-07-30 | Teijin Pharma Ltd | Aktivált szénszálakat tartalmazó, orálisan beadható adszorbens |
| CN104379182B (zh) * | 2012-03-29 | 2017-12-05 | 巴斯夫公司 | 非晶碳承载的包含镧系氧化物的纳米粒子及其制备方法 |
| CN105832767B (zh) * | 2016-04-12 | 2019-03-01 | 贵州泰柏妇科疾病研究中心 | 一种纳米活性炭与石墨烯在抗hpv病毒中的应用 |
| CN105998063B (zh) * | 2016-06-20 | 2019-04-26 | 贵州泰柏妇科疾病研究中心 | 一种纳米活性炭在抑制细菌中的应用 |
| CN105920037B (zh) * | 2016-06-20 | 2019-01-22 | 贵州泰柏妇科疾病研究中心 | 一种纳米活性炭溶胶在制备治疗疱疹病毒药物中的应用 |
| TWI634891B (zh) * | 2017-08-17 | 2018-09-11 | 逢甲大學 | Medicine for treating or preventing colorectal cancer |
| KR101941871B1 (ko) * | 2017-09-05 | 2019-01-24 | 서원대학교산학협력단 | 쌀도정 부산물과 한방생약의 발효 추출물을 포함하는 항혈전용 조성물 |
| WO2020210376A1 (en) * | 2019-04-09 | 2020-10-15 | The Board Of Trustees Of The University Of Illinois | Drug adsorbed highly porous activated carbon for enhanced drug delivery |
| CN114831934B (zh) * | 2022-05-11 | 2023-05-26 | 回音必集团抚州制药有限公司 | 一种盐酸尼卡地平注射液的制备方法 |
| CN115671315B (zh) * | 2023-01-03 | 2023-04-28 | 北京弘堃医药科技有限公司 | 组织释药浓度可控的抗癌药物递送系统及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR215459A1 (es) * | 1976-04-02 | 1979-10-15 | Brewer J | Metodo para producir un agente terapeutico capaz de proporcionar una marca en un animal no humano para indicar la administracion del agente al animal y para proporcionar tambien un repositorio del agente a ser libeberado durante un espacio de tiempo |
| FR2655546B1 (fr) * | 1989-12-11 | 1992-03-13 | Assistance Publique | Composition pour injection intratumorale, et utilisation pour le marquage prechimiotherapique et preoperatoire, en laserotherapie et en thermotherapie. |
| RU2017492C1 (ru) * | 1991-05-14 | 1994-08-15 | Нестерова Ирина Вадимовна | Способ лечения пищевой аллергии |
-
2003
- 2003-05-06 CN CNB031250904A patent/CN1263466C/zh not_active Expired - Fee Related
-
2004
- 2004-01-14 EP EP04701884A patent/EP1652528A1/en not_active Withdrawn
- 2004-01-14 CA CA002524924A patent/CA2524924A1/en not_active Abandoned
- 2004-01-14 KR KR1020057021018A patent/KR20060003072A/ko not_active Application Discontinuation
- 2004-01-14 JP JP2006504190A patent/JP2006525238A/ja not_active Withdrawn
- 2004-01-14 RU RU2005137851/15A patent/RU2005137851A/ru not_active Application Discontinuation
- 2004-01-14 AU AU2004236381A patent/AU2004236381A1/en not_active Abandoned
- 2004-01-14 US US10/507,570 patent/US20050123613A1/en not_active Abandoned
- 2004-01-14 WO PCT/CN2004/000045 patent/WO2004098620A1/zh active Application Filing
-
2005
- 2005-12-05 ZA ZA200509866A patent/ZA200509866B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004236381A1 (en) | 2004-11-18 |
| RU2005137851A (ru) | 2006-06-27 |
| JP2006525238A (ja) | 2006-11-09 |
| WO2004098620A8 (fr) | 2005-01-06 |
| CA2524924A1 (en) | 2004-11-18 |
| CN1263466C (zh) | 2006-07-12 |
| WO2004098620A1 (fr) | 2004-11-18 |
| US20050123613A1 (en) | 2005-06-09 |
| KR20060003072A (ko) | 2006-01-09 |
| EP1652528A1 (en) | 2006-05-03 |
| CN1548057A (zh) | 2004-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200509866B (en) | Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer | |
| WO2007033578A1 (fr) | Metallo-fullerenols et leur application dans la preparation de medicaments visant a inhiber la croissance tumorale | |
| WO2019084038A1 (en) | HIGH-CONCENTRATION VALPROIC ACID SOLUTIONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| WO2020211009A1 (zh) | 痘苗病毒致炎兔皮提取物治疗造血系统损伤的用途 | |
| EP3187187A1 (en) | Adsorbent for oral administration, therapeutic agent for renal diseases and therapeutic agent for hepatic diseases | |
| CN1751741A (zh) | 纳米碳管输液剂、其制备方法及其在治疗癌症、心血管疾病、感染疾病中的应用 | |
| CN1640392A (zh) | 大剂量的羟基红花黄色素a或其可药用盐在缺血引起的急性脑中风的药物中的应用 | |
| Ke et al. | Application of hemoperfusion in the treatment of acute poisoning | |
| CN100560060C (zh) | 纳米级药物微球及其制造方法 | |
| RU2414926C1 (ru) | Гемостимулирующее средство и способ стимуляции гемопоэза | |
| CN101327215B (zh) | 一种含有原小檗碱型生物碱的药物组合物 | |
| CN111449026A (zh) | 一种小型猪急性肾损伤（aki）模型的构建方法 | |
| CN113209046B (zh) | 一种CoSe@BSA纳米粒子药物组合物及其制备方法和应用 | |
| CN1283272C (zh) | 一种抗癌药物及其制备方法 | |
| CN1537541A (zh) | 蒙脱石在制药中的应用 | |
| CN112603998B (zh) | 一种用于治疗血栓的含有曲克芦丁的复方制剂及其制备方法 | |
| Karatieieva et al. | Application of ozone therapy in surgical practice | |
| CN1657100B (zh) | 选择性靶向胃癌和淋巴系统的纳米级制剂及其制备方法 | |
| CN1615907A (zh) | 炭气凝胶输液剂、其制备方法及其应用 | |
| CN1053817C (zh) | 刺五加提取物及其生产工艺以及含有该提取物的注射液和冻干粉针剂 | |
| CN1559510A (zh) | 治疗艾滋病、癌症的复方药物及其制备方法 | |
| Derzsiova et al. | Haemoperfusion of amitriptyline and nortriptyline–an in vitro study | |
| CN1109545C (zh) | 螯合铁的制剂及其制备方法 | |
| JP2004522775A (ja) | 抗癌薬 | |
| JPH03500535A (ja) | 有機燐化合物中毒に対する解毒剤 |